Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) CFO William J. Peters sold 10,000 shares of Amphastar Pharmaceuticals stock in a transaction dated Monday, December 3rd. The shares were sold at an average price of $22.40, for a total transaction of $224,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

AMPH stock opened at $21.47 on Thursday. The stock has a market cap of $989.73 million, a P/E ratio of 56.50 and a beta of 1.42. Amphastar Pharmaceuticals Inc has a 52 week low of $14.40 and a 52 week high of $22.74. The company has a current ratio of 2.02, a quick ratio of 1.34 and a debt-to-equity ratio of 0.10.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings data on Thursday, November 8th. The company reported $0.12 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.01. The firm had revenue of $75.54 million for the quarter, compared to the consensus estimate of $76.84 million. Amphastar Pharmaceuticals had a negative net margin of 2.33% and a positive return on equity of 2.80%. The firm’s revenue was up 30.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.07 earnings per share. On average, equities analysts predict that Amphastar Pharmaceuticals Inc will post -0.06 earnings per share for the current year.

Several analysts have recently weighed in on the stock. Zacks Investment Research downgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, November 13th. Needham & Company LLC set a $25.00 target price on shares of Amphastar Pharmaceuticals and gave the company a “buy” rating in a report on Friday, November 9th. Wells Fargo & Co reaffirmed a “buy” rating on shares of Amphastar Pharmaceuticals in a report on Friday, November 9th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $26.00 target price on shares of Amphastar Pharmaceuticals in a report on Wednesday, November 14th. Finally, BidaskClub raised shares of Amphastar Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, September 5th. One analyst has rated the stock with a sell rating, one has issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $23.60.

A number of hedge funds have recently added to or reduced their stakes in AMPH. Principal Financial Group Inc. boosted its holdings in Amphastar Pharmaceuticals by 2.2% during the first quarter. Principal Financial Group Inc. now owns 273,428 shares of the company’s stock worth $5,127,000 after buying an additional 5,789 shares in the last quarter. Piedmont Investment Advisors LLC purchased a new stake in Amphastar Pharmaceuticals during the second quarter worth about $128,000. State of Wisconsin Investment Board boosted its holdings in Amphastar Pharmaceuticals by 29.3% during the second quarter. State of Wisconsin Investment Board now owns 36,200 shares of the company’s stock worth $552,000 after buying an additional 8,200 shares in the last quarter. Sei Investments Co. boosted its holdings in Amphastar Pharmaceuticals by 4.9% during the second quarter. Sei Investments Co. now owns 67,934 shares of the company’s stock worth $1,037,000 after buying an additional 3,193 shares in the last quarter. Finally, Engineers Gate Manager LP purchased a new stake in Amphastar Pharmaceuticals during the second quarter worth about $387,000. 44.74% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was first published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://www.watchlistnews.com/william-j-peters-sells-10000-shares-of-amphastar-pharmaceuticals-inc-amph-stock/2664973.html.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.

See Also: Diversification

Insider Buying and Selling by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.